Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12/7/8 RNA-dependent RNA polymeraseBiochemical Techniques & Resources Published on 2021-07-162022-10-28 Journal: Biochemical Journal [Category] COVID-19, Fulltext, SARS, [키워드] acute respiratory syndrome Antiviral compound antiviral efficacy approach approved biochemically catalytic complex complexes Compound coronavirus coronavirus disease CoV COVID-19 drug effective enzymatic activity expressed global pandemic growth homologue host cells human cells identify identifying in viral in vitro inhibitor inhibitors lack MONITOR Nsp12 pandemic pharmacological public health purified RdRP Replication repurposing Research RNA virus RNA-dependent RNA polymerase RTC safety profile SARS-CoV-2 SARS-CoV-2 RdRp sequence single-stranded positive-sense small molecule inhibitor Suramin target [DOI] 10.1042/BCJ20210200 PMC 바로가기 [Article Type] Biochemical Techniques & Resources
Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19Review Published on 2021-07-162022-10-30 Journal: Journal of Personalized Medicine [Category] COVID-19, [키워드] accelerate acting administration affected agent anti-SARS-CoV-2 anticipated Antiviral Antiviral agents Antiviral effect antiviral property aplidin B.1.1.7 variant clinical Clinical data clinical evidence Combination COVID-19 current database demonstrated Dexamethasone effective Efficacy Ex vivo hospital hospitalized COVID-19 patients hospitalized patients Host inhibiting interactions intravenous isoform knowledge lack lineages mechanism multicentre Multiple myeloma Patient Plitidepsin Population profile regimen Remdesivir safety profile SARS-CoV-2 Standard of care standard treatment suggested translation Treatment Trial viral load reduction Viral proteins [DOI] 10.3390/jpm11070668 PMC 바로가기 [Article Type] Review
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents청소년에서 BNT162b2 Covid-19 백신의 안전성, 면역원성 및 효능Randomized Controlled Trial Published on 2021-07-152022-09-12 Journal: The New England Journal of Medicine [Category] 임상, 진단, [키워드] 1:1 95% CI 95% confidence interval acute respiratory syndrome Adolescent Adults adverse events age assigned BNT162b2 BNT162b2 vaccine Cohort contribute coronavirus coronavirus disease criterion dose effective effective vaccine Efficacy Emergency use Evidence facilitate fatigue geometric mean ratio greater groups headache immune response Immunity immunogenicity indicated Injection-site pain Injections Mild-to-moderate Neutralizing titer observer-blinded occurred of BNT162b2 participant Placebo placebo recipients placebo-controlled produced PROTECT Randomly reactogenicity receive recipient recipients Safety safety profile SARS-CoV-2 SARS-COV-2 infection Serious Adverse Event severe adverse events Side-effect Trial two-sided Vaccine were assessed [DOI] 10.1056/NEJMoa2107456 PMC 바로가기 [Article Type] Randomized Controlled Trial
Methylene Blue has a potent antiviral activity against SARS-CoV-2 and H1N1 influenza virus in the absence of UV-activation in vitro메틸렌 블루는 시험 관내 UV- 활성화의 부재하에 SARS-COV-2 및 H1N1 인플루엔자 바이러스에 대한 강력한 항 바이러스 활성을 갖는다.Article Published on 2021-07-122022-09-01 Journal: Scientific Reports [Category] SARS, 유전자 메커니즘, 진단, 치료제, [키워드] absence Activation addition antiviral activity Antiviral agents approved blood product blood products blue Cell Clinical studies clinical study Concentration Degradation drug effective EMA European Medicines Agency evaluated examined FDA food genomic RNA H1N1 H1N1 influenza immune Immune Serum in vitro infected with SARS-CoV-2 Influenza influenza virus H1N1 malaria mechanism methemoglobinemia Methylene Methylene blue presence or absence safety profile SARS-CoV-2 SARS-CoV-2 infections serum shown Support therapeutic activity therapeutic efficacy Treatment UV light viral infection virucidal virus viruses [DOI] 10.1038/s41598-021-92481-9 PMC 바로가기 [Article Type] Article
The investigation of mRNA vaccines formulated in liposomes administrated in multiple routes against SARS-CoV-2SARS-CoV-2에 대한 다중 경로로 투여되는 리포솜에 제형화된 mRNA 백신의 조사Article Published on 2021-07-102022-09-12 Journal: Journal of controlled release : official journal o [Category] SARS, 진단, [키워드] administration Administration route Affect cellular immune responses COVID-19 Efficacy and safety Express global public health immunized mice in vivo indicated Intramuscular injection investigated Lipid nanoparticle Liposome liposomes LNP mice mRNA mRNA vaccine mRNA vaccines neutralized neutralizing capacity pandemic Prevent public health crisis RBD Receptor-binding domain safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pseudotyped virus SARS-CoV-2 RBD SARS-CoV-2 vaccine sera specific antibody Th2-type Vaccine virus [DOI] 10.1016/j.jconrel.2021.05.024 PMC 바로가기 [Article Type] Article
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial Research Published on 2021-07-082022-10-05 Journal: Nature Medicine [Category] 바이오마커, 임상, [키워드] Administered Algorithm Analysis baseline change Clinical data conducted confidence interval double-blind Efficacy fat FGF21 fibroblast fibrosis FIVE fraction fusion protein group groups growth factor hepatic fat IMPROVE majority NASH Patient patients Placebo placebo-controlled placebo-controlled study Preclinical Randomized receive reduced reported safety profile significantly statistically significant difference steatohepatitis stratified study drug subcutaneous injection TEAE the placebo group the United State treat Treatment treatment-emergent adverse event Trial [DOI] 10.1038/s41591-021-01425-3 [Article Type] Research
Informing selection of drugs for COVID-19 treatment through adverse events analysis이상반응 분석을 통한 코로나19 치료제 선택 안내Article Published on 2021-07-072022-09-10 Journal: Scientific Reports [Category] 신약개발, 임상, 치료법, 치료제, [키워드] adverse event adverse events Analysis approved calculated caution clinical trial clinical trials collected combating coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient COVID-19 treatment Data mining Data processing databases drug Drug safety drugs effective drug evaluate evaluated FDA Frequency Informing organ pandemic Patient relative frequency reported Safe safety profile significantly statistically Surveillance Treatment Z-score Z-scores [DOI] 10.1038/s41598-021-93500-5 PMC 바로가기 [Article Type] Article
Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers StudyArticle Published on 2021-07-022022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] adverse event AEs anti-COVID-19 vaccine approved assessment Biologic drugs clinician Comirnaty Complete COVID 19 COVID-19 vaccination COVID-19 vaccine demographic characteristics disease Disease activity DMARDs Efficacy evidenced fatigue Fever first dose flare headache Immunosuppressive agents immunosuppressive therapy increased risk Inflammatory information injection Italy myalgia older patient Pain participant Patient patients profile Relapse reported Rheumatic diseases risk Safe Safety safety profile SARS-CoV-2 second dose Severe infection vaccination Vaccinations Vaccine Vaxzevria were recorded [DOI] 10.3390/vaccines9070730 PMC 바로가기 [Article Type] Article
Potential Prophylactic Treatments for COVID-19Covid-19에 대한 잠재적 예방 치료Review Published on 2021-07-022022-09-10 Journal: Viruses [Category] SARS, 치료제, [키워드] accumulate addition Antiviral antivirals approved Asymptomatic Candidates causative agent clinical trial clinically concern conducted coronavirus disease Coronavirus disease 2019 COVID-19 death disease drug Effectiveness Efficacy Emergency Emergency use expected Health Organization Human indication Inflammatory information majority medications Mild molecular morbidity and mortality multi-organ failure outbreak pandemic post-exposure Potential pre-exposure Prophylactic Prophylaxis provided Public public health emergency Repurposed drugs Research respiratory Respiratory droplets Respiratory failure Safe safety profile SARS-CoV-2 severity Spread the SARS-CoV-2 Treatment Vaccine virus World Health Organization [DOI] 10.3390/v13071292 PMC 바로가기 [Article Type] Review
Outcomes and management of immune thrombocytopenia secondary to COVID-19: Cleveland clinic experience코로나19에 따른 면역성 혈소판감소증의 결과와 관리: 클리블랜드 클리닉 경험Article Published on 2021-07-012022-09-11 Journal: Transfusion [Category] SARS, 바이오마커, 진단, [키워드] acquired disease age autoantibodies autoantibody bleeding Blood Blood Transfusion causes characterized Cleveland Clinical characteristics Complete coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 diagnosis COVID-19 patients diagnosed effective Eltrombopag glucocorticoid Glucocorticoids GRADE grade 3 Health Organization hypoxic respiratory failure immune Immune thrombocytopenia Immunoglobulin Intravenous immunoglobulin IVIG male management mechanical ventilation median age median time MOST occurred Patient patients Platelets required Respiratory failure response to treatment safety profile secondary to severity Severity Score Standard standard treatment survived Symptom the median thrombocytopenia Treatment was used WHO World Health Organization [DOI] 10.1111/trf.16368 PMC 바로가기 [Article Type] Article